Sunisam 50 mg Sunitinib Price USA | Ernest Impex Indian Exporter

Sunisam 50 mg Capsule: High-Dose Tyrosine Kinase Inhibition for Global Oncology Care

Are you searching for a reliable Sunisam 50 mg capsule exporter from India? Ernest Impex, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted oncology therapies. We maintain a high-authority, cold-chain-compliant supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that high-potency multi-kinase inhibitors reach medical institutions with pharmaceutical-grade integrity.

Detailed Product Overview: What is Sunisam 50 mg?

Sunisam 50 mg Capsule contains the active ingredient Sunitinib, a potent, oral, multi-targeted tyrosine kinase inhibitor (TKI). Manufactured by Samarth Life Sciences, Sunisam 50 mg is the high-strength formulation designed to aggressively disrupt the signaling pathways that cancer cells utilize for survival, proliferation, and angiogenesis.

For international B2B procurement, Sunisam 50 mg is a vital component in intensive treatment regimens for advanced solid tumors that have shown resistance to primary therapeutic interventions.

Primary Therapeutic Indications

Sunisam 50 mg is clinically utilized globally for the following:

1. Gastrointestinal Stromal Tumor (GIST): For patients whose disease has progressed or who are intolerant to Imatinib Mesylate.

2. Advanced Renal Cell Carcinoma (RCC): Used as a first-line or secondary treatment for metastatic kidney cancer.

3. Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors in patients with unresectable locally advanced or metastatic disease.

Mechanism of Action: Multi-Pathway Signal Interruption

Sunisam 50 mg works through a sophisticated pharmacological process known as Multi-Kinase Inhibition:

• Receptor Blockade: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs), including all receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3) and platelet-derived growth factors (PDGFR-α and -β).

• Anti-Angiogenesis: By blocking the VEGFR pathway, Sunisam 50 mg prevents the tumor from developing the new blood vessels required to sustain its growth.

• Direct Cytotoxicity: It targets the KIT (stem cell factor receptor) and FLT3, which are critical in the growth and survival of gastrointestinal and hematological malignancies.

• Dual-Action Efficacy: This simultaneous attack on both the tumor cells and the tumor blood supply makes it an exceptionally effective targeted therapy for metastatic disease.

Administration and Clinical Safety

• Dosage Protocol: Sunisam 50 mg is typically taken orally, once daily. In GIST and RCC, a common cycle is 4 weeks on treatment followed by 2 weeks off.

• Storage Requirements: Store at room temperature (20°C to 25°C). Ensure the container is tightly closed to protect from moisture and light.

• Key Monitoring Parameters:

• Hepatotoxicity: Liver function tests (ALT, AST, Bilirubin) should be performed regularly.

• Cardiovascular Safety: Monitoring for hypertension and left ventricular ejection fraction (LVEF) is recommended.

• Thyroid Function: Routine screening for hypothyroidism is standard clinical practice.

• Dermatologic Monitoring: Patients should be checked for hand-foot skin syndrome and skin discoloration.

Why Source Sunisam from Ernest Impex?

• Authentic Indian Exporter: Direct access to genuine Samarth Life Sciences inventory, ensuring 100% product authenticity and competitive wholesale pricing for global markets.

• Global Distribution Logistics: We specialize in the complex documentation and cold-chain-secured shipping required for Washington, London, Bangkok, Canberra, Singapore, and Kingston.

• Regulatory Compliance: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary international export permits.

• Bulk Supply Stability: We specialize in large-scale fulfillment for hospital groups, oncology clinics, and regional pharmaceutical distributors.